By Dr. Jeremy Bleicher, DO, MPH
Board-Certified Endocrinologist
Medical Contributor, WeightLossPills.com
When I completed my endocrinology fellowship in 2015, the standard conversation about obesity in a clinical setting went something like this: we would discuss lifestyle modification, perhaps a referral to a dietitian, and if things were severe enough, a conversation about bariatric surgery. The pharmacological options were limited and, frankly, not particularly impressive. Most of my colleagues treated obesity as a background condition, something to note on a problem list while focusing on the downstream consequences — the diabetes, the hypertension, the metabolic syndrome.
That clinical landscape has changed more dramatically in the past five years than in the previous twenty. I have been practicing endocrinology long enough to have a clear before and after, and the after is something I would not have predicted when I was in training. For patients who have spent years feeling like the medical system had little to offer them, I want to explain what has actually changed and where things are going, because the picture is considerably more optimistic than most patients realize.
Why Endocrinologists Were Watching GLP-1 Before Anyone Else
Glucagon-like peptide-1 was not a weight loss concept when endocrinologists first encountered it. It was a diabetes concept. GLP-1 receptor agonists entered clinical practice as glucose-lowering medications for type 2 diabetes, and the weight loss was initially observed as a secondary effect, notable but not the primary goal. Endocrinologists were prescribing early GLP-1 medications for blood sugar control and watching patients lose meaningful amounts of weight as a side effect that no one had quite anticipated at that scale.
This is relevant context because it explains why endocrinologists tend to think about these drugs differently than the general conversation around them suggests. We did not start thinking of them as weight loss medications and then discover they also helped metabolic disease. We started thinking of them as metabolic medications and then realized the weight loss effect was itself treating the metabolic disease. The distinction matters for how we understand what they are actually doing and what the next generation of drugs might accomplish.
What the clinical trial data has made clear over time is that GLP-1 receptor agonists are not simply suppressing appetite. They are changing how the body regulates energy, how fat tissue responds to insulin, how the liver handles glucose, and how the cardiovascular system responds to metabolic stress. The SELECT trial, which showed a 20 percent reduction in major cardiovascular events with semaglutide in patients with obesity but without diabetes, was a landmark finding. It confirmed that treating obesity pharmacologically was not just about the number on the scale. It was about disease outcomes.
What the Current Generation of Drugs Has Revealed About Metabolism
One of the most clinically useful things that has come out of the GLP-1 era is a better understanding of what was going wrong in patients who struggled with weight management for years and could not understand why. The answer, in many cases, is that their hunger and satiety signaling was genuinely dysregulated in ways that were not addressable through willpower or caloric restriction alone. The medications made this visible by demonstrating how dramatically appetite changed when the hormonal environment shifted.
Patients who had described a constant preoccupation with food, an inability to feel satisfied after eating, and an experience of hunger that felt qualitatively different from what thinner people described, were reporting something real. The GLP-1 medications quieted that signal in ways that sometimes surprised even the patients themselves. “I forgot to eat lunch” is a sentence I now hear regularly from patients on these medications. I never heard it before.
This has pushed endocrinologists and obesity medicine specialists to think more carefully about the neurobiology of appetite regulation and what it means for treatment. If the fundamental problem in a significant subset of patients with obesity is a hormonal signaling failure rather than a behavioral one, then the clinical approach needs to target that failure rather than simply asking patients to override it through effort. The drugs that do this most effectively are the ones producing the strongest results, and the relationship is not coincidental.
Diabetes and Obesity: Why Treating One Now Means Treating Both
In my endocrinology practice, the majority of patients with type 2 diabetes also carry a diagnosis of obesity, and the relationship between the two conditions is bidirectional and reinforcing. Excess adipose tissue, particularly visceral fat, drives insulin resistance. Insulin resistance worsens metabolic dysfunction. The resulting hyperinsulinemia promotes further fat storage. For years, we managed these conditions somewhat separately, treating blood sugar with one set of tools and addressing weight with another, often less effective, set.
The GLP-1 medications collapsed that separation in a useful way. A single drug now meaningfully addresses both blood sugar and body weight simultaneously, and does so through mechanisms that reduce cardiovascular risk independently of either effect. For a patient with type 2 diabetes and obesity, a well-chosen GLP-1 agent is doing more clinical work than almost anything else in our pharmacological toolkit.
What this has changed in practice is the conversation I have with newly diagnosed diabetes patients. The framing is no longer: we will start with metformin and see how your sugars respond. The framing is increasingly: we have medications that address the metabolic dysfunction underlying your diabetes, support weight loss that will itself improve your blood sugar, and reduce your cardiovascular risk. That is a fundamentally different clinical conversation, and it produces better engagement and better outcomes.
What Is Coming and Why It Matters for Patients With Complex Metabolic Disease
The pipeline beyond the current approved agents is where things become genuinely exciting from a clinical standpoint, and also where patients with more complex metabolic disease profiles stand to benefit most.
Triple receptor agonists, which simultaneously target GLP-1, GIP, and glucagon receptors, are showing weight loss results in phase trials that exceed what dual agonists produce. For patients with obesity-related metabolic syndrome, where multiple hormonal systems are dysregulated simultaneously, hitting all three pathways may produce improvements in blood sugar, fat metabolism, and energy expenditure that current agents cannot match.
There are also agents in development that target entirely different mechanisms: amylin analogues, which affect satiety signaling through a different pathway than GLP-1; orexin receptor modulators, which influence the brain’s appetite and sleep regulation systems; and combination approaches that pair existing GLP-1 mechanisms with new targets to amplify results. The diversity of the pipeline suggests that the field is genuinely beginning to understand obesity as a complex, multi-system condition and building tools that address it at that level of complexity.
For patients who want to follow what is coming, a well-maintained resource tracking the future weight loss meds in late-stage development can help translate the clinical trial data into practical terms. Understanding which drugs are closest to approval, what mechanisms they use, and what patient profiles they are designed for puts patients in a much stronger position to have informed conversations with their physicians as new options become available.
What I Tell Patients Who Feel Like They Missed the Window
A question I get regularly is some version of: should I wait? A patient who is currently managing their metabolic disease with existing medications sometimes wonders whether they should hold off on adjusting treatment because something better is six months away.
The honest clinical answer is almost always no. The best treatment is the one available now that fits a patient’s profile and that they will take consistently. Waiting for a future drug while current metabolic disease progresses is not a neutral choice. Blood sugar that is poorly controlled today is doing damage today, regardless of what will be available in two years.
What I do tell patients is that the field is moving fast enough that their treatment plan is likely to look different in three to five years than it does today, and that staying engaged with their physician about emerging options is genuinely worthwhile. The drugs that become available in that window may offer meaningfully better outcomes than what is accessible now. But those outcomes only benefit patients who are healthy enough to take advantage of them, which is an argument for treating well today rather than waiting.
The Longer View
I went into endocrinology because I was drawn to conditions that required long-term thinking. Diabetes, thyroid disease, metabolic syndrome: these are not infections you clear in a course of antibiotics. They are conditions you manage over years and decades, and managing them well requires both the physician and the patient to take a genuinely longitudinal view.
What has changed in the past five years is that the tools available for that longitudinal management have improved more rapidly than at any previous point in my career. The gap between what pharmacology can now accomplish and what surgery was historically required to achieve is narrowing. The understanding of why patients struggle with metabolic disease, rather than simply the observation that they do, is deepening. And the pipeline of what is coming next is the most substantive in the field’s history.
For patients who have been in a long struggle with their metabolic health, that is not a small thing. It is a reason to stay engaged and to keep the conversation with your physician open, because the landscape they are navigating with you is genuinely improving.
Dr. Jeremy Bleicher, DO, MPH, is a board-certified endocrinologist specializing in diabetes, thyroid disease, and metabolic syndrome. He completed his endocrinology fellowship at Larkin Community Hospital in Miami and holds dual board certifications from the American Osteopathic Board of Internal Medicine. He practices at Endocrinology Care in South Florida and serves as a medical contributor at WeightLossPills.com.
